Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
40%(4 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_3
5
31%
Ph phase_1
2
13%
Ph not_applicable
1
6%
Ph phase_4
7
44%

Phase Distribution

2

Early Stage

0

Mid Stage

12

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 3Large-scale testing
5(33.3%)
Phase 4Post-market surveillance
7(46.7%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(10)
Terminated(3)
Other(3)

Detailed Status

Completed10
unknown3
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (13.3%)
Phase 35 (33.3%)
Phase 47 (46.7%)
N/A1 (6.7%)

Trials by Status

completed1063%
unknown319%
terminated16%
withdrawn213%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT06331156Phase 3

A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants

Completed
NCT04481191Phase 3

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Completed
NCT03530124Phase 4

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Completed
NCT03239496Phase 3

A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV

Completed
NCT04063150Phase 4

Immunogenicity of Intramuscular and Intradermal IPV

Terminated
NCT04142814Not Applicable

Randomized Controlled Study on T-PEP Versus IPV Method for Lower Respiratory Airways Clearance in Tetraplegic Tracheotomized Spinal Cord Injured Patients

Withdrawn
NCT03890497Phase 4

Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh

Unknown
NCT03310073Phase 4

Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV

Completed
NCT02643446

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine

Completed
NCT03016949Phase 3

A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine

Withdrawn
NCT02477046Phase 3

Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh

Unknown
NCT02412514Phase 4

Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules

Completed
NCT02189811Phase 4

Polio End-game Strategies - Poliovirus Type 2 Challenge Study

Completed
NCT01841671Phase 4

Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine

Unknown
NCT01708720Phase 1

Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults

Completed
NCT01709071Phase 1

Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16